WEST BRIDGEWATER, Mass., June 26 /PRNewswire-FirstCall/-- Boston Biomedica, Inc. (Nasdaq: BBII) today announced that it has been featured in the current (June 24th) issue of BusinessWeek, in a special advertising section entitled "The Equity Investor's 26-Week Micro-Cap Review". Selected profiles of 26 of the nation's top price-performing micro-cap companies were highlighted. According to BusinessWeek: "From the approximate 3700 domestic companies with market capitalizations under 200 million dollars, the following pages highlight selected firms in the top 10%, in terms of share price performance for the 26-week period ending 3/29/02. Each profile describes a leading company including its industry, market trends, and reasons for success, as written by company management. And while past performance is never a guarantee of future results, these top-performing companies represent investment opportunities worthy of a micro-cap investor's close consideration."
Richard T. Schumacher, Founder, CEO, and Chairman of Boston Biomedica, said: "Fewer than 400 publicly traded micro-cap companies nationwide qualified for inclusion in BusinessWeek's semi-annual Equity Investor's Micro-Cap Review. It is certainly an honor to be one of only 26 companies profiled, and a reflection we believe of investors' confidence in BBI, its progress to date, its future prospects and its management team.
Boston Biomedica, Inc. provides products and services for the detection and monitoring of infectious diseases such as AIDS and Viral Hepatitis. BBI has three operating business units: (1) BBI Diagnostics, an ISO 9001 certified manufacturer and supplier of quality control and diagnostics reagents used to increase the accuracy of in vitro diagnostic tests, (2) BBI Biotech Research Laboratories, a research and development center providing R&D support for the other BBI business units, as well as contract research and repository services for the government, industry and other third parties, and (3) BBI Source Scientific, an ISO 9001 certified manufacturer of diagnostic instrumentation and medical devices. In addition, BBI is conducting research and development in Pressure Cycling Technology (PCT), with the goal of introducing new solutions for a number of important healthcare issues, including the extraction of nucleic acids and proteins, the inactivation of pathogens in human plasma, protein purification, food safety, genomics, and proteomics. BBI also maintains a passive investment in Panacos Pharmaceuticals, a privately held antiviral drug and vaccine development company spun-off from BBI in 2000, whose goal is to introduce new solutions for the treatment of infectious diseases.
Statements contained in this news release that state the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future are "forward-looking" statements. It is important to note that the Company's actual results could differ materially from those projected in such forward-looking statements. Factors that could cause actual results to differ from those projected include the possibility that, due to changes in customers' needs and unforeseen cost increases, BBI's core business revenues and profitability may not meet expectations; that due to technological difficulties, BBI may not be successful in developing Pressure Cycling Technology (PCT) into commercially successful products, BBI may not be successful in releasing the first PCT product in 2002, demand for PCT products may not develop as anticipated, or Panacos Pharmaceuticals may not be successful in initiating clinical trials for an anti-HIV compound by year's end. There can be no assurance that Boston Biomedica will maintain a passive investment in Panacos at the current or any level. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and Quarterly Report on Form 10-Q for the three months ended March 31, 2002. Copies of these documents may be obtained by contacting the Company or the SEC.
Visit us at our website http://www.bbii.com
Please email us at IR@bbii.com if you prefer to receive future announcements electronically
Investor Contacts:
Richard T. Schumacher, CEO & Chairman
Kevin W. Quinlan, President & COO
Boston Biomedica, Inc.
508-580-1900 (T)
Media Contact:
Jennifer Viera
Schneider & Associates
jviera@schneiderpr.com
617-536-3300 (T)
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X22214460
SOURCE Boston Biomedica, Inc.
Web site: http: //www.bbii.com
CONTACT: Richard T. Schumacher, CEO & Chairman, or Kevin W. Quinlan, President & COO of Boston Biomedica, Inc., +1-508-580-1900; or Jennifer Viera of Schneider & Associates, +1-617-536-3300, jviera@schneiderpr.com